Member Info for Bella6532

POINT shares closed yesterday at $6.685. Premarket today they are up over 80% to around $12.30.

I wonder if Avacta had any knowledge of this deal?

OK BV...I should have said:

AVA6000 in clinic appears to be consistent with mice study and it looks like AVA3996 could be too.

The ....'no safety issues are apparent'...is Avacta wording from the Poster not mine....

Considering AVA3996 has not gone to clinic yet, Avacta are using quite definite language...

Fingers crossed eh!!!

Go to Summary bottom right of the AVA3996 Poster Presentation...'no safety issues are apparent'...

https://avacta.com/wp-content/uploads/2023/04/AACR-AVA3996-2023-poster.pdf

AVA6000 in clinic is consistent with mice study and it looks like AVA3996 will be too.

Real value is made up of endless possibilities and from where I'm sitting that's what Avacta tech has...

The key is in the lock and it won't be that long before it's well and tuely turned and the door is flung open...

2024 will be that year....

Sorry BV I meant replacement for loss of patent...ie is it something Takeda would be likely to be interested in or one of those pipeline interested parties.

'In 2015, a U.S. judge in Delaware termed the patent as invalid, citing the compound it covers was “the inherent result of an obvious process.” In 2017, Takeda won an appeals court that had termed the patent valid and extended the Velcade patent protections till 2022.'

BV...as you are obviously aware inflammation responses are now being recognized as the precursor to so many nasty debilitating and life threatening diseases including MND.

The Rugby World Cup is great to watch but the consequences of huge inflammation induced trauma can be a killer.

Inflammation is a trigger and it's roll in triggering certain cancers is very much under the microscope and LG's work could be very interesting indeed and they must feel our tech has possibilities.

Looks to me 2024 is going to be a very news worthy year with more Avacta tech going in human.

This is all value creation...

AffyXell hopefully into human in 2024...this is a JV so far more valuable in the long term and puts our affimer tech into the next generation stem cell treatment. Again I don't think the long term value/returns are really understood on this one.

LG Chem partnership/licence deal focusing on oncology and inflammatory diseases...again it moves our tech into yet another sphere. R&D filing hopefully next year which would be first time an affimer is in human.

Proteasomes are the very such toxic drugs.

AVA3996 could be an extremely valuable replacement for Velcade and could easily be licenced before it goes into clinical trials...

Remember...good data/results from AVA6000 trial will unlock the whole platform...

Once the PreCISION concept is proven in humans then licencing can begin...Avacta dorsn't have to be the one taking each one to trial. Avacta just has to develop the concept and produce some pre-clinical data which is what they are doing and they have lots of data coming through especially with affimers etc.

Velcade

It's very likely that 2 week dosing will give even better outcomes...that's got to be far more product cost effective.

The real value is in the PreCISION pipeline...and this could include several new chemo drugs that are so potent they are not currently being used as chemo theropies but PreCISION could allow them to come into usage. Guys why are you not taking this into account.

Tesla...haha...

See what GM thought about Tedla in 2009...a mere 14 years ago...it says it all really about so called experts...

https://markets.businessinsider.com/news/stocks/nikola-steve-girsky-tesla-elon-musk-gm-battery-ev-auto-2023-9

Tesla is a disrupter and Avacta in my opinion is sitting on two major disruptive technologies...

Sheppy...why do you care?

Why are you so concerned about, in your opinion, others bad investment?

I personally couldn't give a rats about anyone elses investments...I only care about mine.

I invest in AIM companies because it's an early stage investment. I've had good and bad investments. The good more than out weighing the bad by a long way. If I make a loss on one I re-evaluate the sell point on another to hopefully cover the loss. Some companies I've been happy to move in and out of quickly...others I've been happy to sit tight on and maybe pick up more shares on the way and it all based on my own research and reading sound research presented by others not a new 30 poster with an selfish agenda. Your concerns play no part in my decision making especially when they are so unfounded.

Jive_turkey...that is why I've always referred to 'potentially a cure'. The mechanisms that cause cancerous cells are somewhat complex and even if the cancerous cells have all been distroyed today there is no guarantee those mechanisms or even others won't click into action again at a later date so yes a 100% cure in all patients in all cancer types in all age groups etc etc is possibly never going to be achievable any time soon. However my use of the wording potentially a cure was more to do with the fact that if you have the means to deliver a cancer distroying dose which can target and potentially totally distroy any cancerous cell in the body then for those who don't experience a reoccurance then it's a cure for them without the need for other treatments.

If 6k moves the odds dial more in favour of survival/non-reocurrance then that too moves the dial in favour of cure for many more people.

Perhaps it is too early to dream but my fingers are well and truely crossed and if that one patient survives then I'm sure he/she will call it a cure.

Nursesteve...'he talked about the mechanism of the Pre|CISION platform he mentioned they could also include a ‘spacer’ that could control the release of the active drug into the tumour environment. '

I haven't yet listerned to the Presentation but from what you heard did this sound as if it could be a continual slow release type spacer...rather than a stop start, stop start spacer. If the former that sounds like a great idea as it wouldn't give the tumour cells time to develop resistance. It would be rather like the difference between trying to put out a fire with buckets of water which have to be refilled each time vs using a hosepipe with a constant flow of water.

Guys....it's potentially a cure...it targets the FAP in the cancer cells whereever they are in the body at whatever stage they are at. Metastised cancer is what kills especially when it appears in vital orders which Dox on it's own may or may not find/target and it it does it can be extremely damaging to the vital order itself...

I've been banging on about this potentially being a cure but not sure the impact has quite been realised.

Anyone who has experienced life with cancer knows that once told it's in remission is often because no obvious tumours can be seen but that's not to say the odd cell or two aren't still lurking undetected.

With every Buy there's a Sell and visa versa...Why people get hooked up on what they think is a sell...what about the buy...

A nice little WORKED order...

It's not losses which cripple early stage companies like Avacta...it's cash flow and lack of cash reserves.

Avacta's two recent purchases came with income streams which not only benefit the DX side of the business they benefit the business as a whole. As a result of the purchases the DX side of the business in the near term is projected to move into profitability together with expansion.

It looks like the markets are, like many on here, completely ignoring the day to day factors which are the back bone of the company and only looking at the bsiness from it's ongoing clinical trial standpoint. They don't like agreements with ND clauses, they don't like uncertainty regarding debt payments. In fact, they don't like early stage clinical trials because that's where most products fail. The markets are cautious and that's why they tend to stick to FTSE Listings rather than push the boat out on AIM. They do like fundraisers...buying at a discount and selling back to PI's at a profit often by creating a bit of a buying frenzy...

For me, it's now just a waiting game. I have enough invested as a not too bad price and will simply wait for data news in Q4 (probably a nice Christmas pressy), then start of Phase 2....anything juicey in the meantime will be a bonus.

Am out for lunch so will miss the live Presentation but will catch up with it later...enjoy...

‘ Antibiotic resistance is a major global challenge and there are good future growth prospects for the market for antimicrobial resistance ("AMR") testing and is a key area in which Avacta expects to grow the Coris business. ‘

‘Avacta will transfer its lateral flow product development activities to Coris and support that activity through ongoing development of Affimer® reagents for new products or to enhance existing ones.’

mmm!!!! Antibiotic Resistance testing using affimer based kits???...